|
Prostate Cancer
Prostate Cancer
|
olaparib
Prostate Cancer Prostatic Dis - 3 weeks
|
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
|
Peritoneal Cancer
Peritoneal Cancer
|
|
|
Peritoneal Cancer
Peritoneal Cancer
|
|
|
Fallopian Tube Cancer
Fallopian Tube Cancer
|
|
|
Ovarian Cancer
Ovarian Cancer
|
|
|
Ovarian Cancer
Ovarian Cancer
|
|
|
Ovarian Cancer
Ovarian Cancer
|
olaparib
Sensitive: B - Late Trials
|
|
Ovarian Cancer
Ovarian Cancer
|
rucaparib
Sensitive: B - Late Trials
|
|
Ovarian Cancer
Ovarian Cancer
|
ABT-888
Sensitive: B - Late Trials
|
|
Ovarian Cancer
Ovarian Cancer
|
atezolizumab
Resistant: B - Late Trials
|
|
Ovarian Cancer
Ovarian Cancer
|
CPB
Sensitive: B - Late Trials
|
|
Triple Negative Breast Cancer
Triple Negative Breast Cancer
|
olaparib
Sensitive: C1 - Off-label
|
|
Ovarian Cancer
Ovarian Cancer
|
tislelizumab + BGB-290
Sensitive: C2 – Inclusion Criteria
|
|
Triple Negative Breast Cancer
Triple Negative Breast Cancer
|
tislelizumab
Sensitive: C2 – Inclusion Criteria
|
|
Ovarian Cancer
Ovarian Cancer
|
bevacizumab + niraparib
Sensitive: C2 – Inclusion Criteria
|
|
Non Small Cell Lung Cancer
NSCLC
|
talazoparib
Resistant: C3 – Early Trials
|
|
Gastric Cancer
Gastric Cancer
|
nivolumab
Sensitive: C3 – Early Trials
|
|
Triple Negative Breast Cancer
Triple Negative Breast Cancer
|
pembrolizumab + niraparib
Sensitive: C3 – Early Trials
|
|
Prostate Cancer
Prostate Cancer
|
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
|
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate
Resistant: C3 – Early Trials
|
|
Ovarian Cancer
Ovarian Cancer
|
ABT-767
Sensitive: C3 – Early Trials
|
|
Ovarian Cancer
Ovarian Cancer
|
PARP inhibitor
Sensitive: C3 – Early Trials
|
